Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: QRX
News: Latest news
Web Site: QRxPharma Ltd
Other Articles: 06-01-201010-12-200913-11-2009

RSS - Subscribe to the News Today on Proactive UK ▼

Monday March 15, 10:21Diamondcorp: a big cash injection and a lot of work to do

70% of the new money was raised from current shareholders, reflecting a hefty amount of faith in the management to deliver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Monday March 15, 11:38Calvin Klein owner buys Tommy Hilfiger for US$3 billion from Apax Partners

The New York listed shirt and neckwear company is paying €1.924 billion in cash and issuing €276 million in PVH common stock (approximately 8.7 million shares) to fund the transaction.

 

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Monday March 15, 08:01China's growth boosting commodity prices

The latest economic figures from China have put pressure on the dollar and boosted a number of high-yielding currencies, including the Australian dollar and the South African rand.

FULL ARTICLE ►
QRxPharma Ltd

QRxPharma Ltd

QRxPharma Limited (ASX: QRX; OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.  The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales.  QRxPharma’s lead drug compound, MoxDuo™ IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

 

CLICK HERE FOR FULL ANALYSIS OF QRXPHARMA LTD
Wednesday, January 06, 2010

Australian Ethical Investments lodges substantial shareholder notice with QRxPharma

company news image

QRxPharma (ASX: QRX; OTCQX: QRXPY) has received a notice of substantial shareholder from Australian Ethical Investment fund managers.

The fund became a substantial holder on 18 December 2009, acquiring 5.279m shares in QRx at $0.80 per share.

In November 2009, QRxPharma completed an underwritten institutional placement at A$0.80 per share, raising A$8.0 million which was significantly oversubscribed.

Proceeds from the Placement and Rights Issue (which in total raised raised A$21.6 million) will be used for funding
the Phase 3 drug development and expenditure programme for its MoxDuo™ IR (immediate release dual opioid) product.

This includes the lodgement of a New Drug Application with the US Food and Drug Administration in 2010, and for additional working capital purposes.

QRxPharma plans for launch of MoxDuo™ IR in the US marketplace in 2011.

MoxDuo™ IR is intended for the management of moderate to severe acute pain. QRxPharma’s product pipeline also includes intravenous (IV) and controlled release (CR) formulations which are in earlier stages of clinical development.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other QRxPharma Ltd articles


Other QRxPharma Ltd news

More news ►

Investors interested in QRxPharma Ltd recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.